Introduction:
Introduction:
Most cutaneous melanoma tumors have BRAF V600 mutations (1). This results in constitutive BRAF activity and downstream MAPK pathway activation, independent of upstream stimuli. BRAF inhibitors in combination with MEK inhibitors was proposed to overcome BRAF inhibitor resistance (Nazarian et al, Nature 2010) and clinically is superior to BRAF inhibitor monotherapy against BRAF V600 -mutant tumors (2-4). However, acquired resistance to the BRAF and MEK inhibitor combination is still common (5), consistent with MAPK pathway-redundant resistance mechanisms as important clinically (6, 7). Several resistance mechanisms have been identified which result in MAPK pathway reactivation, such as NRAS mutation or BRAF alternative splicing (6, (8) (9) (10) (11) (12) . These MAPK-reactivating alterations only explain ~50% of BRAFi-resistance mechanisms (5) (7). Some MAPK-redundant resistance mechanisms result from cancer cell intrinsic, epigenomically driven, adaptive responses to drug pressure early during therapy (6) and likely result in wide-ranging phenotypic switches in melanoma with acquired MAPK inhibitor resistance in patients who relapse of such therapies (7).
Melanoma cells grown without drug pressure stochastically switch between a rapid-cycling cell state and a rare slow-cycling cell state (13). Treatment with a BRAF inhibitor selects for cells in the slow cycling state (6, 12).
These data are further supported by the observation that BRAFi/MEKi-resistant cells and tumors can be resensitized to treatment with BRAF or MEK inhibitors after a "drug holiday" (14-16).
The RhoA subfamily (RhoA, RhoB, and RhoC) GTPases act as molecular switches which regulate actin dynamics. In this report, we will use RhoA to refer to the whole subfamily. In melanoma, the RhoA subfamily promotes invasion and metastasis (17) (18) (19) , and inhibition of RhoA signaling suppresses tumor growth (20).
RhoB is upregulated upon short-term vemurafenib treatment, and RhoB silencing sensitizes cells to BRAF and MEK inhibitors (21) . Canonically, RhoA GTPases promote the formation of actin stress fibers by promoting Gactin polymerization and inhibiting F-actin depolymerization (22) (23) (24) . Actin stress fibers are increased in melanoma cells with acquired BRAFi resistance (25).
In addition to regulating actin dynamics, RhoA GTPases also regulate gene transcription. This is, in part, through actin polymerization-dependent activation of MRTF and YAP1. MRTF and YAP1 are transcriptional co-activators which, upon activation, translocate into the nucleus and regulate gene transcription. Silencing of MRTF or SRF, a transcription factor by which MRTF modulates gene expression, prevents melanoma metastasis (26). Previously, we have developed a series of MRTF-pathway inhibitors including CCG-203971 and CCG-222740 (27-29) . We have demonstrated that CCG-203971 prevents melanoma metastasis, induces G1
cell cycle arrest, and reduces growth of melanoma cells (28) . When bound to G-actin, MRTF is sequestered in the cytoplasm due to masking of the MRTF nuclear localization signal by G-actin. Upon RhoA-mediated F-actin polymerization, the cytosolic G-actin pool is depleted resulting in MRTF dissociation from G-actin, and translocation into the nucleus (26, (30) (31) (32) (33) . YAP1 is also activated upon F-actin polymerization, but through a different mechanism (34) (35) (36) . YAP1 has been shown to promote BRAFi/MEKi resistance in melanoma through suppression of apoptosis via BCL-xL and BIM dysgulation (7, 25, 37, 38) , and positive enrichment/accumulation of YAP1 signature/protein has been documented in about 40% of clinical melanoma samples from patients who relapsed on MAPK inhibitor therapies (7) Sox10 is a neural crest lineage transcription factor, which is highly expressed in melanocytes and some melanoma cells (39) and Sox10 loss has been associated with BRAFi inhibitor resistance. Melanoma cells with high Sox10 expression are more proliferative and Sox10 knockdown reduces melanoma cell proliferation (40) (41) (42) . Interestingly, there is an inverse relationship between Sox10 expression and Sox9 expression and these two proteins reduce each other's expression (41). A subset of melanoma cells is in a transient slow-cycling, predrug-resistant state which are epigenetically poised to become drug-resistant (6, 13). Upon BRAFi treatment, these cells are transformed into a stable resistant state, which is initiated with loss of Sox10-mediated gene transcription, later followed by increased AP-1-and TEAD-mediated gene transcription. These findings highlight that Sox10 is lost early during the development of BRAFi resistance. Another study demonstrated that Sox10 silencing promotes BRAFi resistance, in part through activation of TGFβ signaling (43). Interestingly, TGF-β can indirectly activate RhoA (44, 45) .
Previous studies have demonstrated that non-mutational, acquired resistance mechanisms represent a major hurdle in maintaining a durable response to MAPK-directed therapeutics (7). One major acquired resistance mechanism may be activation of the RhoA pathway. In this study we build upon existing literature to demonstrate that actin stress fiber accumulation and RhoA signaling is elevated in approximately half of vemurafenib-resistant melanoma cell lines tested and that this mechanism is also operational in clinical tumors.
RhoA
High but not RhoA Low -resistant lines are partially resensitized to vemurafenib by two structurally distinct CATATAGGAGAAGGCCGAGTAGA-3'). Primers were designed using the Harvard Primer Bank tool (https://pga.mgh.harvard.edu/primerbank/). Fold-change analysis was performed using the Δ Δ CT method.
RNA-Seq sample preparation and data processing
Total cellular RNA was extracted from UACC62P and UACC62R cells (two biological replicates per cell line) using the same method which was used for qPCR experiments. RNA concentration was measured by Qubit and quality control was performed on an Agilent 2100 Bioanalyzer in the MSU Genomics Core. Sequencing was performed at a depth of >30M reads/sample. Quality control was performed on the FastQ files using FastQC v0.11.5, and reads were trimmed using Trimmomatic v0.33. Reads were mapped using HISAT2 v2.1.0 and analyzed using HTSeq v0.6.1. Differential gene expression was calculated using edgeR. Raw RNASeq reads and processed HTSeq read counts are available on GEO under GSE115938.
Immunoblotting
Cells were cultured and treated as indicated, placed on ice, and rinsed once in cold PBS. Cells were lysed in 2x
Laemmli Sample Buffer (Biorad, #1610737). Samples were sonicated with a probe sonicator for approximately 5 sec, then boiled at 100 ºC for 10 min. Samples were loaded onto a 12% polyacrylamide gel and transferred to
Immobilon-FL PVDF Membrane (Millipore Sigma, #IPFL00010). Membranes were blocked in 5% BSA + TBS-Tween (1:1000) for 1 h, then incubated in primary antibody overnight at 4 ºC. Membranes were washed 3x
Plates were incubated for 5 min at room temperature then briefly centrifuged (4000 rpm, 60 seconds) before being read on a Bio-Tek Synergy Neo plate reader. Data are plotted versus Vemurafenib concentration for each treatment condition. The Area Under the Curve (AUC) was calculated for each curve using GraphPad Prism.
Bioinformatics

Dataset Processing
Cancer Cell Line Encyclopedia (CCLE) gene expression Affymetrix CEL files (Version 19-Mar-2013) were downloaded from the Broad Institute CCLE data portal. CEL files were processed using Affymetrix Expression Console (Build 1.4.0.38). Probe IDs were collapsed to gene names using the CollapseDataset function on
GenePattern. The TCGA RNA-Seq dataset for cutaneous melanoma (SKCM) was downloaded from the UCSC Cancer Genome Browser portal. No further data processing was performed prior to analysis.
RNA-Seq data for 62 human tumors paired for pre-and post-MAPK inhibitor resistance was downloaded from GSE65185 (7). Analysis of these data was performed on the pre-processed CuffnormFPKM dataset included in this series. RNA-Seq data for in vitro generated vemurafenib-resistant M229P/R and M238P/R cells was downloaded from GSE75313 (6). These data were processed using the above described RNA-Seq data processing pipeline. GenePattern with all parameters left as default. The ssGSEA output values were z-score normalized.
A RhoA/C gene signature was generated by using all genes which are upregulated > 2-fold by overexpression of either RhoA or RhoC from the GSE5913 dataset in NIH-3T3 cells. These two lists were merged, and duplicates were removed. This resulted in a list of 79 genes (Supplemental Table 1 ).
A Sox10 gene signature was created using the 96 h gene expression data in GSE37059 in M010817 cells. The 214 genes downregulated > 2-fold when Sox10 expression was knocked down were taken as the Sox10 signature (Supplemental Table 1 ). Following ssGSEA and z-score normalization, the sign of the signature score was inverted so that a positive signature score indicates high predicted Sox10 activity and a negative signature score indicates low predicted Sox10 activity.
Differential gene expression between the vemurafenib-sensitive and resistant pairs UACC62P/R, M229P/R, and M238P/R was calculated using the edgeR package. The top 500 differentially expressed genes for each cell line pair were stratified into lists of upregulated and downregulated genes. The intersection of all upregulated or downregulated genes among the three cell lines was determined resulting in 54 genes which were downregulated in all three resistant cell lines ('Downregulated_In_Resistant' signature) and 34 genes that were upregulated in all three resistant cell lines ('Upregulated_In_Resistant' signature) (Supplemental Table 1 ).
The YAP1 signature used was the CORDENONSI_YAP_CONSERVED_SIGNATURE in the C6 collection on MSigDB. The MRTF signature is comprised of all genes downregulated > 2-fold upon MRTF knockdown in B16F2 melanoma cells (26) (Supplemental Table 1 ).
Drug Response Signatures
Gene expression profiling and drug IC50s were downloaded from the GDSC data portal (https://www.cancerrxgene.org/downloads). Gene expression data was median centered so that the median expression of each gene was equal to 0. Data was randomly divided into a training (80%) and test (20%) set. A predictive model was built on the training set for each compound (n = 265 compounds) using a random forest algorithm (randomForest package in R) with ntrees = 500 and mtry = sqrt(#genes). Each model was validated on the test dataset by calculating the Pearson correlation coefficient between the predicted and actual IC50s.
Models with a Pearson correlation coefficient > 0.3 were considered predictive. A full table of these results is included as (Supplemental Table 2 ). To use gene expression data to predict drug response on clinical tumors, the TCGA SKCM data were median-centered using the same method used on the GDSC training data. Since the TCGA and GDSC datasets were collected on different gene expression analysis platforms, the two datasets were filtered to include only overlapping genes. Models from GDSC which were deemed predictive for a drug response were then projected onto the TCGA dataset. TCGA samples were stratified by Sox10 expression (Sox10 Low = Sox10 expression is >1 SD below mean, Sox10 High = Sox10 expression is all other samples). The average predicted IC 50 for the Sox10 Low and Sox10 High tumors was calculated by averaging the predicted log(IC 50 ) for each sample class.
Statistical Analysis
Most bioinformatics analysis was performed using R v3.3.0. Data analysis and statistics were performed using GraphPad Prism v6 or v7. Dose response curves were fit using nonlinear least square regression [log(agonist) expression (see fig 1D) . Statistical analysis was performed with an unpaired t-test. F) MRTF and YAP1 signatures were predicted for human melanoma tumor pairs which had an increase in RhoA/C signature score from Fig. 1G . Change in MRTF and YAP1 signature score between baseline and resistant tumors is plotted. 
Results:
RhoA activation in BRAFi-resistant melanoma cells and tumors. We generated vemurafenib-resistant melanoma cells by exposing them to vemurafenib (2 µM). After two months, this resulted in a population of cells that grew well in the presence of vemurafenib. One of the resistant cell lines (UACC62R) had a flattened morphology when compared to the parental cell line, while a different cell line (SK-Mel-19R) displayed no obvious morphological changes from its parental counterpart. Since cell shape is largely controlled through modulation of the actin cytoskeleton, we examined F-actin structure by staining the cells with fluorescently labeled phalloidin. UACC62R cells showed a marked increase in actin stress fiber positive cells compared to the parental line, while there was no effect in SK-Mel-19R cells compared with parental control cells (Fig. 1A) .
We then expanded this panel to include three other vemurafenib-resistant cell line pairs (M229, M238, and M249) which were previously generated using similar methods (8). Two of the three resistant cell lines (M229R, and M238R) showed an increase in actin stress fibers similar to our observations in UACC62R cells, while M249R cells had no change in actin stress fiber-positive cells (Fig. 1B) . Actin stress fibers are primarily controlled by RhoA family activation. Another readout of RhoA activation is MLC2 phosphorylation and pMLC2 S18/19 is increased in UACC62R (actin stress fiber-positive) cells, but not in SK-Mel-19R (actin stress fiber-negative) cells (Fig. 1C) . Taken together, these data showed that the RhoA pathway is activated in a 3 of 5 vemurafenib-resistant cells.
To more broadly confirm this finding, we correlated sensitivity to PLX4720 (a BRAF inhibitor which is structurally similar to vemurafenib) with the gene expression results of 38 BRAF V600 -mutant cell lines from the Cancer Cell Line Encyclopedia (CCLE). Genes which are highly expressed in PLX4720-resistant cells (genes with a Pearson correlation of gene expression values vs drug activity area < -0.5) were analyzed by Gene
Ontology and KEGG pathway analysis. One of the most statistically significant GO terms was "small GTPase mediated signal transduction" (Fig. 1D ) and the most statistically significant KEGG pathway was "Regulation of actin cytoskeleton" (Fig. 1E) . A RhoA/C gene signature is also inversely correlated (R = 0.42) with PLX4720 sensitivity (Fig. 1F) . Collectively, these data suggest that our phenotypic observations are more broadly applicable in a wider panel of cell lines and that RhoA activation is positively correlated with BRAFi resistance.
To determine whether these cell line observations are applicable in the clinical context, we analyzed RNA-seq data from 41 tumors before and after development of resistance to BRAFi/MEKi (7). More than half of the resistant tumors (n = 24) had an increased RhoA/C signature score over the baseline tumor (Fig. 1G) . Taken together, these data suggest that RhoA is activated in approximately half of BRAFi-resistant cells and tumors, and that RhoA activation is inversely correlated with BRAFi sensitivity. This is a more comprehensive approach to measure the effect of the drug combination since this measurement is sensitive to changes in both IC 50 and E max . All three actin-stress-fiber positive resistant lines were re-sensitized to vemurafenib by either Y-27632 (Fig. 2J) or Fasudil (Fig. 2K) , however, neither ROCKi re-sensitizes M249R
ROCK inhibition sensitizes RhoA
(actin stress fiber-negative) cells. Taken together, these results indicate that ROCK inhibition selectively resensitizes RhoA High vemurafenib-resistant cells, but not RhoA Low cells.
Sox9/Sox10 expression switch in RhoA High vemurafenib-resistant cells. We next wanted to understand mechanistically why the RhoA pathway is only activated in a subset of vemurafenib-resistant cells. We performed RNA-seq on UACC62P/R cells and found that a number of genes involved in melanocyte differentiation and melanoma biology including TYR, POSTN, WNT5A, AXL, SOX9, SOX10, and several collagen isoforms were up-or down-regulated. Among these, SOX10 is one of the most significantly downregulated genes in UACC62R cells (Fig. 3A) . Sox10 has been previously linked to vemurafenib resistance in a mechanism that is partially dependent on TGFβ-pathway activation (43) and as a part of an epigenomedriven transcriptomic reprogramming (6). We also discovered that Sox9 is one of the most significantly upregulated genes in UACC62R cells (Fig. 3A) . Since Sox9 and Sox10 expression levels are reportedly mutually antagonistic (41), we wanted to determine whether the inverse relationship between Sox9 and Sox10 expression is observed in BRAFi-resistant melanoma cells. This finding also held up in a larger panel of cell
lines. Of the five tested, only the three cell lines with RhoA activation show upregulated Sox9 and downregulated Sox10 (Fig. 3B ). This result also holds true at the protein level; Sox10 is downregulated in UACC62R, M229R, and M238R cells, but not in M249R cells (Fig. 3C ). To extend these observations to clinical melanomas, we stratified SKCM tumors in the TCGA RNA-Seq dataset into Sox10 Low (> 1 SD below mean expression) and Sox10 High tumors (all others) (Fig. 3D ). The Sox10 Low tumors (n = 17) have significantly increased Sox9 expression, demonstrating that the inverse relationship we observe in BRAFi-resistant cell lines also extends to human melanoma tumors (Fig. 3E) . The small number of Sox10 Low tumors may be due to the fact that the tumors the TCGA SKCM dataset are BRAFi/MEKi-treatment naïve. Sox10 Low TCGA tumors also have increased RhoA/C gene signature enrichment scores (Fig. 3F) . We then assessed RhoA/C and Sox10 activation signatures on the single cell level using a melanoma single cell RNA-Seq dataset (46). It was necessary to use a Sox10 signature instead of Sox10 expression itself due to the low sequence coverage in single cell sequencing experiments. There is a strong inverse correlation between Sox10 activation and RhoA/C activation signatures (Fig. 3G ).
We then wanted to identify drugs that selectively target Sox10 Low tumors, since this would give insight into the signaling pathways activated in these cells and would identify potential therapeutics which could be used to reverse or prevent BRAFi-resistance. We generated gene expression signatures to predict drug response for 265 common anti-cancer drugs. Then we projected these signatures onto the TCGA dataset to find drugs that are predicted to selectively target Sox10 Low tumors. Four of the top six drugs predicted to be selective for Sox10
Low cells inhibit either ROCK or SRC. These drugs are GSK269963 (ROCKi), Y-39983 (ROCKi), GASK269962
(SRCi), and Dasatinib (SRCi) (Fig. 3H ). (Fig. 4C) . These include the YAP1/MRTF target gene CYR61 and genes encoding proteins which activate RhoA (ARHGEF12, GNA11, GNA12, TGFβ1) as well as YAP1 and YES1.
To test whether YAP1 and MRTF are activated in human tumors, we determined/calculated YAP1 and MRTF signature activation in TCGA tumors. Sox10 Low tumors have elevated YAP1 and MRTF signature gene expression ( Fig. 4D/E ). YAP1 and MRTF activation was predicted on the paired pre-and post-resistance human melanoma tumors which had an increase in RhoA/C signature gene expression (Fig. 4F) . Out of this subset of tumors, only 3/24 displayed neither activation of YAP1 or MRTF target genes. Half (12/24) of the tumors had predicted activation of both YAP1 and MRTF, which could possibly result from the high degree of redundancy in the transcriptional output from YAP1 and MRTF or subpopulation heterogeneity. Some appeared to have selective activation of YAP or MRTF, which is interesting considering the apparent mutual exclusivity of MRTF-A/YAP1 activation in our cell line models (Fig. 4A/B localization. YAP1's nuclear localization is decreased in both cell lines upon dasatinib treatment (Fig. 5A/B) .
We next wanted to determine whether dasatinib re-sensitizes Sox9
High /Sox10 Low BRAFi-resistant cells to Vemurafenib. Dasatinib treatment has only a minor effect on potentiating the vemurafenib response in the 1 parental UACC62P and M229P cells (Fig. 5C/E) . However, the vemurafenib response is greatly potentiated in the resistant UACC62R and M229R cells (Fig. 5D/F Future studies will be necessary to elucidate details of these signaling networks. While it is already known that YAP1 promotes BRAFi resistance, these studies build upon that knowledge to demonstrate that dasatinib blocks the nuclear accumulation of YAP1 in BRAFi-resistant cells. Since dasatinib is already FDA-approved for other indications, it highlights the potential of re-purposing this drug for the treatment of BRAFi/MEKi-resistant melanoma. These studies also link MRTF-A activation to BRAFi resistance for the first time, highlighting the potential of targeting MRTF-mediated transcription to prevent or treat drug resistant melanoma. In total, these studies provide robust predictions of precision therapy approaches to prevent or treat clinical BRAFi resistance based on pharmacological inhibition of RhoA-mediated gene transcription. . N a z a r i a n R , 2  0  1  3  ;  2  3  (  1  3  ) : I  D  :  2  3  7  0  7  2  5  8  ;  P  M  C  I  D  :  P  M  C  3  7  0  7  3  9  6  .  2  8 . 
